ENDO: Thyroid Hormone Use May Up Mortality Risk in Older Adults
Increased risk for death seen for visits on LT4 versus those with isolated elevated TSH who were untreated.
Thyroid Disease
First Treatment for Thyroid Eye Disease Gets FDA Approval
The Food and Drug Administration (FDA) has approved Tepezza™ (teprotumumab-trbw; Horizon Therapeutics) for the treatment of thyroid eye disease. Tepezza™, a fully human monoclonal antibody, works by binding to insulin-like growth factor 1 receptor and blocking its activation and signaling. The treatment is administered as an intravenous infusion. The approval of Tepezza™ was supported by…
Solution Formulation of Levothyroxine Sodium Injection Now Available
Fresenius Kabi has announced the availability of Levothyroxine Sodium Injection Solution in 100mcg per 5mL, 200mcg per 5mL and 500mcg per 5mL single-dose vials.
Thyroid Hormones Not Endorsed for Subclinical Hypothyroidism
Almost all adults with SCH would not benefit from treatment with thyroid hormones
Liquid Levothyroxine Formulation Now Available to Treat Hypothyroidism
Tirosint-SOL (levothyroxine sodium oral solution) has been made available by IBSA Pharma for the treatment of hypothyroidism and pituitary thyrotropin suppression.
Hypothyroidism Treatment No Longer Available
The manufacturing discontinuation was a business decision made by the Company.
FDA: Thyroid Medications Recalled Due to Inconsistent Potency
Westminster Pharmaceuticals announced a recall of all lots of Levothyroxine and Liothyronine (Thyroid Tablets) 15mg, 30mg, 60mg, 90mg, 120mg as the product was manufactured using active pharmaceutical ingredients (API) from a company that was found to have deviated from the Food and Drug Administration (FDA)’s Good Manufacturing Practices. FDA laboratory tests confirmed Sichuan Friendly Pharmaceutical’s…
Cancer Development Linked to Increased Diabetes Risk
In the first 2 years after cancer diagnosis, the excess risk for diabetes was highest, and it remained elevated throughout follow-up.
Hypoparathyroidism Treatment Granted Orphan Drug Designation
TransCon PTH is a long-acting prodrug of parathyroid hormone designed to restore PTH to physiologic levels, normalizing blood and urinary calcium levels, serum phosphate levels and bone turnover.
